AMES, Iowa, Nov. 10, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer, announced today that the company will participate in the 2015 World Pancreatic Cancer Day, Friday, Nov. 13, to promote awareness and unite the world in the fight against pancreatic cancer, the nation’s fourth leading cause of cancer-related deaths.
Started by a consortium of international patient advocacy groups, World Pancreatic Cancer Day was developed with the sole purpose of promoting awareness of pancreatic cancer.
“NewLink Genetics is fully committed to raising awareness of pancreatic cancer and finding new treatment options for patients,” said Charles Link, M.D., CEO and Chief Scientific Officer of NewLink Genetics. “We encourage our employees, friends and family members to participate in World Pancreatic Cancer Day by wearing purple and learning more about this devastating disease.”
By 2020, pancreatic cancer is expected to become the second-leading cause of cancer-related deaths in the U.S. Last year, approximately 40,000 people died from pancreatic cancer in the U.S. Each year, it is estimated that 240,000-270,000 people are diagnosed with pancreatic cancer worldwide.
To help promote education, patient and industry groups are working on several initiatives to help bring attention to this deadly cancer. To help, people are encouraged to wear purple on Nov. 13 and follow the conversation on social media channels with #WPCD and #WageHope. You can:
- Follow @WorldPancreatic on Twitter
- Like World Pancreatic Cancer Day on Facebook
- Join the World Pancreatic Cancer Day event on Facebook
- Visit WorldPancreaticCancerDay.org
About NewLink Genetics Corporation
NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immuno-oncology products to improve the lives of patients with cancer. NewLink Genetics' portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink Genetics' product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. For more information, please visit http://www.newlinkgenetics.com.
About World Pancreatic Cancer Day
World Pancreatic Cancer Day is a day dedicated to raising global awareness of pancreatic cancer, and takes place during November, which is Pancreatic Cancer Awareness Month. Driven by a committee of patient advocacy organizations from around the world, the day seeks to start an online conversation about the need for awareness to spur research and advocacy for pancreatic cancer.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of NewLink that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “target,” “potential,” “will,” “could,” “should,” “seek” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about NewLink Genetics’ financial guidance for 2015; enrollment in or results of its clinical trials for product candidates; its timing of release of data from ongoing clinical studies; its plans related to moving additional indications into clinical development; NewLink Genetics’ future financial performance, results of operations, cash position and sufficiency of capital resources to fund its operating requirements; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink makes due to a number of important factors, including those risks discussed in “Risk Factors” and elsewhere in NewLink Genetics’ Annual Report on Form 10-K for the year ended December 31, 2014 and other reports filed with the U.S. Securities and Exchange Commission (SEC). The forward-looking statements in this press release represent NewLink's views as of the date of this press release. NewLink anticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing NewLink Genetics’ views as of any date subsequent to the date of this press release.
Corporate Contact: Jack Henneman Chief Financial Officer, NewLink Genetics 515-598-2561 Investor@linkp.com Investors: Donna LaVoie LaVoieHealthScience 617-374-8800, ext. 107 email@example.com Media: David Connolly LaVoieHealthScience 617-374-8800, ext. 108 firstname.lastname@example.org
Source:NewLink Genetics Corporation